Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) announced that GENSCI Singapore, a wholly-owned subsidiary of the company's holding subsidiary Jinsai Pharmaceutical, and Baosheng Pharmaceutical intend to sign an “Asset Sale Agreement” and “Supply Agreement”. Baosheng Pharmaceutical will transfer the intellectual property rights (including trademarks, etc.) of the pharmaceutical marketing license holder (MAH) held by Baosheng Pharmaceutical (“Meshia®”) worldwide other than Hungary (“scope region”) exclusive to this product SCI Singapore At the same time, GENSCI Singapore authorized Baosheng Pharmaceutical to manufacture and supply this product for a long time.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.